3 top FTSE 250 shares to buy right now

I think the FTSE 250 is offering some great dividend and growth shares at the moment. And there are plenty I see as undervalued.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I mostly invest in shares paying good dividends these days, and the FTSE 250 offers some attractive ones. And with the mid-cap index being generally better known for its growth candidates, I’m seeing plenty of those too now that it’s down.

Looking for FTSE 250 shares to invest in today, the following three would make it on to my shortlist.

A dividend share

I last looked at Jupiter Fund Management (LSE: JUP) in April, when the share price was down. Since then, it’s fallen another 20%. Jupiter shares have now declined by 41% over the past 12 months.

Investment managers tend to fall out of favour when economic conditions turn tough. With interest rates rising and many investors looking for safety, Jupiter has seen an outflow of funds. And that drain on the company might not be over yet.

But the share price fall has pushed the dividend yield to 10.7% now. That’s based on last year’s dividend, which was covered 1.85 times by earnings. I think I see a reasonable safety buffer there, should this year’s dividend decline, while still leaving a good yield.

Should Jupiter reduce its payout, I’d expect the share price to suffer further falls. But I reckon a downturn is a great time to buy FTSE 250 fund managers.

A growth share

With aviation in chaos and airlines in the news, when it comes to growth shares I’m immediately drawn to easyJet (LSE: EZJ).

The latest troubles, including staffing problems, flight cancellations, and threatened strike action, have depressed the easyJet share price further. We’re now looking at a 56% fall over the past 12 months. Oh, and it’s down 70% over five years.

But the airline’s summer update seemed reasonably cheery. It seems that “demand for travel has returned with April and May passengers seven times the same months last year“. In a lot of ways, it’s the quick recovery in demand that’s behind the operational problems hitting airlines now.

The company expects Q3 capacity to be up around 87% of 2019 levels, reaching 90% by Q4. It’s hard to put a valuation on the shares with a loss expected this year. And there are clearly short-term risks. But if volumes do recover as hoped, I think this could be a good time for investors to buy.

A value share

Searching among FTSE 250 shares on low price-to-earnings (P/E) ratios, I’m drawn to Centamin (LSE: CEY).

The gold miner’s share price has dropped 23% over 12 months. On forecasts, that indicates a P/E of only around nine. And the dividend looks set to yield 5.8%.

It’s probably down to the lacklustre performance of gold this year. At $1,830 per ounce, it’s below where we might expect it to be in times like the present, when investors are typically seeking safety.

But if the current economic squeeze should continue, precious metals prices may yet rise significantly above current levels. And that could push Centamin shares to a higher level. On the risk side, Centamin’s production costs are not the lowest in the business. So sustained gold weakness could send it down further.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended Jupiter Fund Management. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 for a Stocks and Shares ISA? Here’s how to try and turn it into a monthly passive income of £493

Hundreds of pounds in passive income a month from a £20k Stocks and Shares ISA? Here's how that might work…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£5,000 put into Nvidia stock last Christmas is already worth this much!

A year ago, Nvidia stock was already riding high -- but it's gained value since. Our writer explores why and…

Read more »

Investing Articles

Are Tesco shares easy money heading into 2026?

The supermarket industry is known for low margins and intense competition. But analysts are bullish on Tesco shares – and…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Can this airline stock beat the FTSE 100 again in 2026?

After outperforming the FTSE 100 in 2025, International Consolidated Airlines Group has a promising plan to make its business more…

Read more »

Investing Articles

1 Stocks and Shares ISA mistake that will make me a better investor in 2026

All investors make mistakes. The best ones learn from them. That’s Stephen Wright’s plan to maximise returns from his Stocks…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I asked ChatGPT if £20,000 would work harder in an ISA or SIPP in 2026 and it said…

Investors have two tax-efficient ways to build wealth, either in a Stocks and Shares ISA or SIPP. Harvey Jones asked…

Read more »

Investing Articles

How much would I need invested in an ISA to earn £2,417 a month in passive income?

This writer runs the numbers to see what it takes in an ISA to reach £2,417 a month in passive…

Read more »

Investing Articles

Rolls-Royce shares or Melrose Industries: Which one is better value for 2026?

Rolls-Royce shares surged in 2025, surpassing most expectations. Dr James Fox considers whether it offers better value than peer Melrose.

Read more »